查核點抑制劑抗藥性癌症市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031年

全球查核點抑制劑抗藥性癌症市場預計將從 2025 年的 352.5 億美元成長到 2031 年的 574.8 億美元，複合年成長率為 8.49%。

該市場涵蓋用於治療經免疫查核點抑制劑初始治療後復發或進展的惡性腫瘤的療法。該領域的根本驅動力在於免疫療法擴大被納入一線治療標準，從而導致符合挽救性治療條件的患者數量不斷增加。美國癌症協會 (ACS) 估計，到 2024 年，美國將新增 2,001,140 例癌症病例，這凸顯了龐大的患者群體將推動對持續治療方案的需求。

然而，該行業面臨著與疾病進展的複雜生物學特徵相關的重大挑戰。阻礙市場成長的主要障礙是腫瘤微環境中觀察到的抗藥性機制的高度多樣性。這種異質性使得藥物研發人員難以識別通用生物標記並開發有效的聯合通訊協定。

市場促進因素

市場成長的主要驅動力是患者群體不斷擴大，而這又得益於第一線免疫療法的日益普及。隨著免疫查核點抑制劑成為多種惡性腫瘤早期階段的標準治療方案，接受此類治療期間或治療後病情進展的患者數量將會增加，從而形成一個需要補救治療的特殊患者群體。這迫使研發公司優先開發能夠克服獲得性抗藥性的藥物。例如，默克公司於2024年4月發布的2024年第一季季財報顯示，Keytruda的全球銷售額達到69億美元，年增20%，顯示一線療法的廣泛應用將為後續治療提供大量潛在候選患者。

同時，戰略聯盟的激增和對下一代免疫腫瘤學研究的資金籌措，正推動著一系列聯合治療的蓬勃發展。研發人員正積極收購T細胞銜接器和抗體藥物複合體（ADC）等資產，以繞過抑制早期查核點抑制劑的腫瘤微環境。默克公司於2024年1月宣布以約6.8億美元收購Harporn Therapeutics，旨在推進其針對免疫療法抗藥性固態腫瘤的T細胞銜接器產品組合，這便是這一趨勢的一個典型例證。這項投資活動與新治療方法臨床療效的持續驗證一致。例如，Iovance BioTherapeutics在2024年2月發布的新聞稿中指出，其細胞療法Amtagvi在先前接受過PD-1抑制劑抗體治療的轉移性黑色素瘤患者中取得了31.5%的客觀緩解率。

市場挑戰

腫瘤微環境中抗藥性機制的巨大多樣性對全球查核點抑制劑抗藥性癌症市場的成長構成了重大障礙。這種生物異質性使藥物研發過程複雜化，這意味著對一位患者有效的治療通訊協定往往由於免疫逃脫途徑的差異而對另一位患者無效。因此，研究人員難以檢驗能夠可靠預測患者對挽救性治療反應的通用生物標記物，迫使研發人員進行更大規模、高成本、耗時更長的臨床試驗來證明統計學意義，這常常導致監管核准和產品上市延遲。

此外，難以對抗藥性類型進行分類限制了新藥的目標患者群體，並限制了新興療法的推廣應用。根據癌症研究所 (CRI) 2024 年的報告，約 45% 的新確診癌症患者可能適合接受免疫療法，但腫瘤抗藥性的複雜性仍然使絕大多數患者無法獲得有效的治療方案。這項限制阻礙了市場收入潛力，因為如果沒有精準且統一的生物標的支持，企業很難將治療方法推廣到更廣泛的難治性患者群體。

市場趨勢

個人化mRNA新抗原疫苗聯合治療的進展正逐漸成為恢復抗藥性惡性腫瘤免疫辨識的關鍵策略。與標準免疫療法不同，這些疫苗根據患者的腫瘤特徵編碼特定的新抗原，激活T細胞攻擊那些已逃避常規抑制的細胞。隨著研發人員與PD-1抑制劑合作以提高疫苗的持久性，這種方法正獲得越來越多的關注。根據默克公司2024年6月發布的新聞稿，數據顯示，在III/IV期高風險黑色素瘤患者中，與Pembrolizumab單藥治療相比，mRNA-4157 (V940) 與Keytruda聯合治療可將復發或死亡風險降低49%。

同時，將抗體藥物複合體（ADC）策略性地納入免疫療法後的治療方法，正在重塑查核點抑制劑治療後晚期癌症患者的治療模式。 ADC 透過將細胞毒性藥物直接遞送至表達抗原的癌細胞，提供了一種繞過導致查核點抗藥性的免疫抑制微環境的機制，使其成為對持續免疫治療無反應的固體癌的首選挽救療法。吉利德科學公司在 2024 年 8 月發布的第二季財報中宣布，其 ADC 藥物 Trodervi 的銷售額成長了 23%，達到 3.2 億美元，這標誌著這一轉變的到來。此成長主要得益於轉移性三陰性乳癌二線治療領域的需求，許多患者在用盡初始免疫治療方案後需要有效的治療。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球查核點抑制劑癌症市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（PD-1抑制劑、PD-L1抑制劑、其他）
  • 適用疾病（肺癌、膀胱癌、惡性黑色素瘤、何傑金氏淋巴瘤等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美抗癌藥物查核點抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲查核點抑制劑抗藥性癌症市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區抗癌藥物查核點抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲地區查核點的市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲查核點抑制劑抗藥性癌症市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球查核點抑制劑抗藥性癌症市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Bristol-Myers Squibb Company.
• AstraZeneca plc.
• Merck KGaA
• F. Hoffmann-La Roche Ltd
• Regeneron Pharmaceuticals Inc
• Pfizer Inc
• Janssen Global Services, LLC
• 4SC AG
• Mirati Therapeutics, Inc.
• Ascentage Pharma

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Checkpoint Inhibitor Refractory Cancer Market is projected to expand from USD 35.25 billion in 2025 to USD 57.48 billion by 2031, registering a CAGR of 8.49%. This market comprises therapeutic agents designed to treat malignancies that relapse or progress following initial treatment with immune checkpoint blockades. The sector is fundamentally driven by the rising integration of immunotherapies into first-line standards of care, which subsequently increases the population of patients eligible for salvage treatments. According to the American Cancer Society, the projection of 2,001,140 new cancer cases in the United States in 2024 highlights the substantial patient base fueling the demand for consecutive therapy lines.

However, the industry faces significant hurdles related to the complex biology of disease progression. A major obstacle impeding market growth is the high variability of resistance mechanisms found within the tumor microenvironment. This heterogeneity complicates the ability of pharmaceutical developers to identify universal biomarkers and create effective combination protocols.

Market Driver

A primary accelerator for the market is the expansion of the addressable patient pool resulting from increased frontline immunotherapy adoption. As immune checkpoint inhibitors become the standard of care for earlier stages of various malignancies, the number of patients eventually progressing on or after these therapies rises, creating a distinct population in need of salvage interventions and compelling developers to prioritize agents that overcome acquired resistance. For instance, Merck's 'First Quarter 2024 Financial Results' in April 2024 reported a 20% increase in worldwide Keytruda sales to $6.9 billion, illustrating the massive scale of frontline adoption that feeds the pipeline of patients potentially eligible for subsequent lines of therapy.

Simultaneously, a surge in strategic alliances and funding for next-generation immuno-oncology research is driving a robust pipeline of combination therapies. Developers are actively acquiring assets such as T-cell engagers and antibody-drug conjugates to bypass the immunosuppressive tumor microenvironment that renders initial checkpoint blockade ineffective. Exemplifying this trend, Merck announced in January 2024 that it invested approximately $680 million to acquire Harpoon Therapeutics to advance a portfolio of T-cell engagers targeting immunotherapy-resistant solid tumors. This investment activity aligns with continued clinical validation of new modalities, as evidenced by Iovance Biotherapeutics' February 2024 press release stating that the cell therapy Amtagvi achieved an objective response rate of 31.5% in metastatic melanoma patients previously treated with a PD-1 blocking antibody.

Market Challenge

The extensive variability of resistance mechanisms within the tumor microenvironment presents a formidable barrier to the growth of the Global Checkpoint Inhibitor Refractory Cancer Market. This biological heterogeneity implies that a treatment protocol effective for one patient often fails in another due to differing immune evasion pathways, thereby complicating the pharmaceutical development process. Consequently, researchers struggle to validate universal biomarkers that can reliably predict patient response to salvage therapies, forcing developers to conduct larger, costlier, and longer clinical trials to prove statistical significance, which frequently delays regulatory approvals and commercial product launches.

Furthermore, the inability to easily categorize resistance types restricts the addressable patient pool for new agents and limits the scalability of emerging drugs. According to the Cancer Research Institute in 2024, while approximately 45 percent of newly diagnosed cancer patients were eligible for immunotherapy, the intricate nature of tumor resistance continues to exclude the majority from effective treatment options. This limitation hampers market revenue potential, as companies cannot readily scale therapies across broader refractory populations without the aid of precise, unified biological targets.

Market Trends

The advancement of personalized mRNA neoantigen vaccines in combination settings is emerging as a critical strategy to restore immune recognition in resistant malignancies. Unlike standard immunotherapies, these vaccines encode specific neoantigens from a patient's tumor profile, priming T-cells to attack cells that have evaded prior blockade, an approach gaining momentum as developers pair vaccines with PD-1 inhibitors to enhance durability. According to a Merck press release in June 2024, data showed that the combination of mRNA-4157 (V940) and Keytruda reduced the risk of recurrence or death by 49% compared to pembrolizumab alone in patients with high-risk stage III/IV melanoma.

Concurrently, the strategic integration of Antibody-Drug Conjugates (ADCs) into post-immunotherapy regimens is reshaping the landscape for patients progressing after checkpoint inhibition. By delivering cytotoxic payloads directly to antigen-expressing tumor cells, ADCs provide a mechanism to bypass the immunosuppressive microenvironment responsible for checkpoint resistance, making them a preferred salvage therapy in solid tumors where continued immunotherapy is ineffective. Highlighting this shift, Gilead Sciences reported in its 'Second Quarter 2024 Financial Results' in August 2024 that sales of the ADC Trodelvy rose 23% to $320 million, primarily driven by demand in second-line metastatic triple-negative breast cancer where patients frequently require effective interventions after exhausting initial immune-based options.

Key Market Players

• Bristol-Myers Squibb Company.
• AstraZeneca plc.
• Merck KGaA
• F. Hoffmann-La Roche Ltd
• Regeneron Pharmaceuticals Inc
• Pfizer Inc
• Janssen Global Services, LLC
• 4SC AG
• Mirati Therapeutics, Inc.
• Ascentage Pharma

Report Scope

In this report, the Global Checkpoint Inhibitor Refractory Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Checkpoint Inhibitor Refractory Cancer Market, By Type

• PD-1 Inhibitor
• PD-L1 Inhibitor
• Others

Checkpoint Inhibitor Refractory Cancer Market, By Application

• Lung Cancer
• Bladder Cancer
• Melanoma
• Hodgkin Lymphoma
• Others

Checkpoint Inhibitor Refractory Cancer Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Checkpoint Inhibitor Refractory Cancer Market.

Available Customizations:

Global Checkpoint Inhibitor Refractory Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Checkpoint Inhibitor Refractory Cancer Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (PD-1 Inhibitor, PD-L1 Inhibitor, Others)
  • 5.2.2. By Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Checkpoint Inhibitor Refractory Cancer Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Checkpoint Inhibitor Refractory Cancer Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Checkpoint Inhibitor Refractory Cancer Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Checkpoint Inhibitor Refractory Cancer Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Checkpoint Inhibitor Refractory Cancer Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bristol-Myers Squibb Company.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca plc.
• 15.3. Merck KGaA
• 15.4. F. Hoffmann-La Roche Ltd
• 15.5. Regeneron Pharmaceuticals Inc
• 15.6. Pfizer Inc
• 15.7. Janssen Global Services, LLC
• 15.8. 4SC AG
• 15.9. Mirati Therapeutics, Inc.
• 15.10. Ascentage Pharma

16. Strategic Recommendations

17. About Us & Disclaimer